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Abstract
Cancer cells induce a set of adaptive response pathways to survive in the face of stressors due to
inadequate vascularization1. One such adaptive pathway is the unfolded protein (UPR) or
endoplasmic reticulum (ER) stress response mediated in part by the ER-localized transmembrane
sensor IRE12 and its substrate XBP13. Previous studies report UPR activation in various human
tumors4-6, but XBP1's role in cancer progression in mammary epithelial cells is largely unknown.
Triple negative breast cancer (TNBC), a form of breast cancer in which tumor cells do not express
the genes for estrogen receptor, progesterone receptor, and Her2/neu, is a highly aggressive
malignancy with limited treatment options7, 8. Here, we report that XBP1 is activated in TNBC
and plays a pivotal role in the tumorigenicity and progression of this human breast cancer subtype.
In breast cancer cell line models, depletion of XBP1 inhibited tumor growth and tumor relapse and
reduced the CD44high/CD24low population. Hypoxia-inducing factor (HIF)1α is known to be
hyperactivated in TNBCs 9, 10. Genome-wide mapping of the XBP1 transcriptional regulatory
network revealed that XBP1 drives TNBC tumorigenicity by assembling a transcriptional complex
with HIF1α that regulates the expression of HIF1α targets via the recruitment of RNA polymerase
II. Analysis of independent cohorts of patients with TNBC revealed a specific XBP1 gene
expression signature that was highly correlated with HIF1α and hypoxia-driven signatures and that
strongly associated with poor prognosis. Our findings reveal a key function for the XBP1 branch
of the UPR in TNBC and imply that targeting this pathway may offer alternative treatment
strategies for this aggressive subtype of breast cancer.
We determined UPR activation status in several breast cancer cell lines (BCCL). XBP1
expression was readily detected in both luminal and basal-like BCCL, but was higher in the
latter which consist primarily of TNBC cells and also in primary TNBC patient samples
(Fig. 1a, b). PERK but not ATF6 was also activated (Extended Data 1a) and transmission
electron microscopy revealed more abundant and dilated ER in multiple TNBC cell lines
(Extended Data 1b). These data reveal a state of basal ER stress in TNBC cells.
XBP1 silencing impaired soft agar colony forming ability and invasiveness (Extended Data
1c) of multiple TNBC cell lines, indicating that XBP1 regulates TNBC anchorage-
independent growth and invasiveness. We next used an orthotopic xenograft mouse model
with inducible expression of two XBP1 shRNAs in MDA-MB-231 cells. Tumor growth and
metastasis to lung were significantly inhibited by XBP1 shRNAs (Fig. 1c-e, Extended Data
1d-g). This was not due to altered apoptosis (Caspase 3), cell proliferation (Ki67) or
hyperactivation of IRE1 and other UPR branches (Fig. 1e, Extended Data 1h, i). Instead,
XBP1 depletion impaired angiogenesis as evidenced by the presence of fewer intratumoral
blood vessels (CD31 staining) (Fig. 1e). Subcutaneous xenograft experiments using two
other TNBC cell lines confirmed our findings (Extended Data 1j, k). Importantly, XBP1
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tsilencing in a patient-derived TNBC xenograft model (BCM-2147) significantly decreased
tumor incidence (Fig. 1f, Extended Data 1l, m).
TNBC patients have the highest rate of relapse within 1-3 years despite adjuvant
chemotherapy7, 8. To examine XBP1's effect on tumor relapse following chemotherapeutic
treatment, we treated MDA-MB-231 xenograft bearing mice with doxorubicin and XBP1
shRNA. Strikingly, combination treatment not only blocked tumor growth but also inhibited
or delayed tumor relapse (Fig. 2a).
Tumor cells expressing CD44high/CD24low have been shown to mediate tumor relapse in
some instances11-13. To test whether XBP1 targeted the CD44high/CD24low population, we
examined the mammosphere-forming ability of cells derived from treated tumors (day 20).
Mammosphere formation was increased in doxorubicin treated tumor cells, while tumors
treated with doxorubicin plus XBP1 shRNA displayed substantially reduced mammosphere
formation (Fig. 2b), a finding confirmed using another chemotherapeutic agent, paclitaxel
(Extended Data 2a, b). Hypoxia activates the UPR, and XBP1 knockdown also dramatically
reduced mammosphere formation in hypoxic conditions (Extended Data. 2b). Furthermore,
CD44 expression was reduced in XBP1-depleted tumors (Extended Data 2c).
To further interrogate XBP1's effect on CD44high/CD24low cell function, we used mammary
epithelial cells (MCF10A) carrying an inducible Src oncogene (ER-Src), where v-Src is
fused with the estrogen receptor ligand binding domain14. Tamoxifen (TAM) treatment
results in neoplastic transformation and gain of a CD44high/CD24low population that has
been previously associated with tumor-initiating properties15. In transformed MCF10A-ER-
Src cells, XBP1 splicing was increased in CD44high/CD24low population (Fig. 2c), while
XBP1 silencing reduced the CD44high/CD24low fraction (Extended Data 2d, e) and markedly
suppressed mammosphere formation (Extended Data 2f), phenotypes not attributable to a
direct effect of XBP1 on cell viability (Extended Data 2g, h). Furthermore, limiting dilution
experiments demonstrated loss of tumor-seeding ability in XBP1-depleted cells (Fig. 2d).
CD44high/CD24low cells sorted from TNBC patient samples confirmed increased XBP1
splicing and other UPR markers, and XBP1 silencing impaired mammosphere-forming
ability (Fig. 2e, f, Extended Data 3a). Conversely, XBP1s overexpression in CD44low/
CD24high cells resulted in gain of mammosphere-forming ability and increased resistance to
doxorubicin treatment (Extended Data 3b, c). Strikingly, patient derived CD44low/CD24high
cells overexpressing XBP1s, but not control parental cells, initiated tumor formation in
immunodeficient mice (Extended Data 3d, e). These data establish a critical role of XBP1 in
CD44high/CD24low cells within TNBC.
ChIP-seq and motif analysis of XBP1 in MDA-MB-231 cells revealed statistically
significant enrichment of both the HIF1α and XBP1 motifs (Fig. 3a, Extended Data 4a),
suggesting frequent colocalization of HIF1α and XBP1 to the same regulatory elements.
HIF1α is hyperactivated in TNBCs, required for the maintenance of CD44high/CD24low
cells9, 10, 16, 17 and regulated in response to microenvironmental oxygen levels. XBP1 ChIP-
seq was therefore also performed in MDA-MB-231 and Hs578T cells cultured under
hypoxia and glucose deprivation conditions for 24h. Exposure to these stressors increased
XBP1 splicing, resulting in a corresponding increase in signal intensity (Extended Data 4b-f)
Chen et al. Page 3
Nature. Author manuscript; available in PMC 2014 October 03.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tand further enrichment of HIF1α motifs in TNBC (Fig. 3a), but interestingly not in luminal
breast cancer cells (Extended Data 4g).
HIF1α motif enrichment in the XBP1 ChIP-seq dataset suggested that XBP1 and HIF1α
might interact within the same transcriptional complex. Co-IP experiments revealed a
physical interaction of HIF1α, but not HIF2α, with XBP1 in 293T cells co-expressing HIF1
and XBP1s cultured under hypoxic conditions, also observed with endogenous proteins in
two TNBC cell lines: MDA-MB-231 and Hs578T (Fig. 3b, Extended Data 4h-j). Subcellular
fractionation revealed that this interaction occurs in the nucleus, and that unspliced XBP1u
protein was not detectable (Extended Data 4k, l). GST pull-down experiments showed that
HIF1α interacts with the XBP1s N-terminus b-zip domain (Extended Data 4m, n).
We next established that XBP1 and HIF1α co-occupied several well-known HIF1α targets
using ChIP-qPCR (Extended Data 5a-c). ChIP-re-ChIP assays using anti-XBP1s followed
by anti-HIF1α antibodies confirmed that XBP1s and HIF1α simultaneously co-occupy these
common targets (Extended Data. 5d). DNA-pull down assays with an HIF1α18 specific
probe precipitated XBP1s in MDA-MB-231 nuclear extracts under hypoxia, indicating their
presence in the same complex (Extended Data 5e, f). XBP1 depletion by two independent
shRNA constructs dramatically reduced hypoxia response element (HRE) luciferase activity
under hypoxia (Fig. 3c). Conversely, XBP1s expression dose-dependently transactivated the
HRE reporter (Extended Data 5g, h), confirming that XBP1 augments HIF1α activity.
When we profiled the differential transcriptome induced by XBP1 silencing in MDA-
MB-231 cells, gene set enrichment analysis identified significant enrichment of HIF1α
mediated hypoxia response pathway genes (Fig. 3d, Extended Data 6a). XBP1 depletion
downregulated HIF1α targets VEGFA, PDK1, GLUT1, and DDIT4 expression in both
normoxic and hypoxic conditions (Extended Data 6b), and these results were validated in
breast cancer xenografts (Fig. 3e) and Hs578T cells (Extended Data 6c). However, XBP1
depletion in luminal tumors did not affect these targets (Extended Data 6d).
To further explore the consequences of this cooperation, we examined how XBP1 or HIF1α
loss affected the transcription of common target genes. We found that high occupancy by
XBP1 was associated with increased occurrence of the HIF1α motif across the genome in
TNBC (Fig. 3f). While XBP1 depletion had no immediate effect on HIF1α expression, it
substantially attenuated concurrent HIF1α and RNA polymerase II occupancy (Extended
Data 6e-g, Fig. 3g). Similarly, XBP1 and RNA Polymerase II occupancy at co-bound sites
was likewise reduced in the absence of HIF1α under hypoxic conditions (Fig. 3h, Extended
Data 6h-l). These results indicate that the assembly of the XBP1-HIF1α complex on target
promoters is crucial for their transcription, via the recruitment of RNA polymerase II.
To establish whether HIF1α contributes to XBP1's function in TNBC, we performed rescue
experiments using a HA-tagged constitutively activated hydroxylation-mutant HIF1α
construct (HA-HIF1α dPA: P402A/P564A). XBP1 splicing was not directly regulated by
HIF1α (Extended Data 7a-c). Enforced overexpression of HIF1α dPA in XBP1 depleted
cells restored expression of HIF1α targets and rescued anchorage independent growth,
mammosphere-forming ability, angiogenesis and in vivo tumor growth (Fig. 3i; Extended
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tData 7d-h). Conversely, HIF1α silencing in XBP1s overexpressing cells dramatically
compromised their ability to sustain mammosphere formation (Extended Data 7i). Hypoxia
is a physiological UPR inducer in cancer19and XBP1s co-localizes with hypoxia marker
CA9 in tumors20. Our experiments demonstrate that XBP1 functions to sustain the hypoxia
response via regulating the HIF1α transcriptional program (Extended Data 8), which ensures
maximum HIF activity and adaptive responses to the cytotoxic microenvironment of solid
tumors.
Integrated analysis of XBP1 ChIP-seq data and gene expression profiles identified 96 genes
directly bound and up-regulated by XBP1. This gene set was defined as the XBP1 signature
(Fig. 4a, Supplementary Table 1). Its expression was highly correlated with hypoxia-driven
signatures in TNBC (Pearson's correlation coefficient=0.61; p=2.28×10-60), but not in ER+
breast cancer patients (coefficient=0.03; p=0.64) (Extended Data 9a, b). Survival analysis
using an aggregate breast cancer dataset for 193 TNBC patient samples21 demonstrated that
tumors with an elevated XBP1 signature displayed shorter relapse-free survival (Log-rank
test, p =0.00677) (Fig. 4b). Cox regression analysis showed that association of the signature
with relapse free survival remained significant after controlling for tumor size, grade and
chemotherapy treatment (p=0.00453, Supplementary Table 2). These findings were
validated in a separate cohort of 190 TNBC patients (Fig. 4c). Importantly, the XBP1
signature did not correlate with clinical outcome of ER+ breast cancer patients (p=0.553)
(Extended Data 9c), indicating its specific prognostic value for TNBC. Expression of the
XBP1-regulated HIF1α program was also associated with decreased relapse free survival
only in TNBC (p=0.00911) (Fig. 4d, Extended Data 9d). Although XBP1 silencing also
affects luminal breast cancer growth, it does so via a mechanism not involving HIF1α
(Extended Data 10, 4g, 6d).
In conclusion, we uncover a key function for XBP1 in the tumorigenicity, progression and
recurrence of TNBC and identified XBP1's control of the HIF1α transcriptional program as
the major mechanism. XBP1 pathway activation correlates with poor patient survival in
TNBC patients implying that UPR inhibitors in combination with standard chemotherapy
may improve the effectiveness of anti-tumor therapies.
METHODS
Cell Culture And Treatments
The non-transformed breast cell line MCF10A contains an integrated fusion of the v-Src
oncoprotein with the ligand-binding domain of the estrogen receptor (ER-Src). These cells
were grown in DMEM/F12 medium supplemented with 5% donor horse serum (Invitrogen),
20 ng/ml epidermal growth factor (EGF) (R&D systems), 10 μg/ml insulin (Sigma), 100
μg/ml hydrocortisone (Sigma), 100 ng/ml cholera toxin (Sigma), 50 units/ml penicillin/
streptomycin (Gibco), with the addition of puromycin (Sigma). Src induction and cellular
transformation was achieved by treatment with 1 μM 4-OH tamoxifen (TAM), typically for
36h as described previously14.
All breast cancer cells were from ATCC cultured according to Neve et al.24. Following
retroviral or lentiviral infection, cells were maintained in the presence of puromycin (2
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tμg/ml) (Sigma). For all hypoxia experiments, cells were maintained in an anaerobic chamber
(Coy laboratory) with 0.1% O2. For glucose deprivation experiments, cells were maintained
in DMEM without glucose medium (Gibco) with 10% FBS (Gibco) and 50 units/ml of
penicillin/streptomycin.
ChIP and ChIP-seq
ChIP was performed with XBP1 antibody (Biolegend, 619502); HIF1α antibody (Abcam,
ab2185), RNA Polymerase II antibody (Millipore, 05-623) or GST antibody (santa cruz,
sc-33613) as described25. See list of primers used in Fig. 3 (Supplementary Table 3). ChIP-
seq libraries were prepared using ChIP-Seq DNA Sample Prep Kit (Illumina). XBP1 ChIP-
seq peaks were first identified using MACS package with a p-value cutoff of 1×10-7 on
individual replicate. Correlations of the ChIP-seq signal in the union peak regions between
two biological replicates are: MDA-MB-231_untreated: 0.97 (p<2.2×10-16); MDA-
MB-231_HG: 0.96 (p<2.2×10-16); Hs578T_HG: 0.98 (p<2.2×10-16); T47D_HG: 0.99
(p<2.2×10-16). The correlations were calculated by cor.test() function in R (http://www.r-
project.org/). The highly confident common peaks between replicates were further identified
using an irreproducible discovery rate (IDR) cutoff of 20%. IDR is a statistical measure that
assesses the consistency of the rank orders of the common ChIP-seq peaks between two
replicates. The methodology and details of the implementation of IDR can be found in26.
Tumor Initiation Assay Using Patient-Derived Tumors
Tumorgraft line BCM-2147 was derived by transplantation of a fresh patient breast tumor
biopsy (ER-PR-HER2-) into the cleared mammary gland fat pad of immune-compromised
SCID/Beige mice and retained the patient biomarker status and morphology across multiple
transplant generations in mice. To overcome the challenge of limited cell viability by
dissociation of solid tumors, 10 mg tumor pieces containing 1.3 × 105 cells were
transplanted with basal membrane extract (Trevigen, Gaithersburg, MD). The cell number
was calculated as average cell yield 1.3 × 107 cells/gram × 0.01 gram = 1.3 × 105 cells. For
sustained siRNA release in the first two weeks following transplantation, porous silicon
particles loaded with siRNA (scrambled control or XBP1 siRNA) packaged in
nanoliposomes were injected into the tumor tissue with basal membrane extract at the time
of transplantation. Scrambled sequence [5’ CGAAGUGUGUGUGUGUGGCdTdT 3’];
XBP1 siRNA sequence [5’ CACCCUGAAUUCAUUGUCUdTdT 3’]. Two weeks post-
transplantation, nanoliposomes containing siRNA (15mg per mouse) were injected I.V.
twice weekly for 8 weeks. Mice were monitored thrice weekly for tumor development, and
tumors were calipered and recorded using LABCAT Tumor Analysis and Tracking System
v6.4 (Innovative Programming Associates, Inc., Princeton, NJ). Tumor incidence is reported
at 10 weeks post-transplantation. The human patient samples were procured and utilized
according to approved IRB protocols for research in human subjects.
Invasion Assay
We performed invasion assays according to14. Invasion of the matrigel was conducted by
using standardized conditions with BD BioCoat growth factor reduced MATRIGEL
invasion chambers (PharMingen). Assays were conducted according to manufacturer's
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tprotocol, by using 5% horse serum (GIBCO) and 20 ng/ml EGF (R&D Systems) as
chemoattractants.
Colony Formation Assay
1×105 breast cancer cells were mixed 4:1 (v/v) with 2.0% agarose in growth medium for a
final concentration of 0.4% agarose. The cell mixture was plated on top of a solidified layer
of 0.8% agarose in growth medium. Cells were fed every 6 to 7 days with growth medium
containing 0.4% agarose. The number of colonies was counted after 20 days. The
experiment was repeated three times and the statistical significance was calculated using
Student's t test.
Subcutaneous Xenograft Experiments
MCF10A ER-Src TAM-treated (36h) cells or MDA-MB-436 or HBL-100 breast cancer cells
were injected subcutaneously in the right flank of athymic nude mice (Charles River
Laboratories). Tumor growth was monitored every five days and tumor volumes were
calculated by the equation V(mm3)=axb2/2, where a is the largest diameter and b is the
perpendicular diameter. When the tumors reached a size of ~100mm3 (15 days) mice were
randomly distributed into 3 groups (5 mice/group). The first group was used as control (non-
treated), the second group was intratumorally treated with shCtrl and the third group was
intratumorally treated with shXBP1. For each injection 10ug of shRNA was mixed with 2ul
of vivo-jetPEI (polyethylenimine) reagent (cat. no 201-50G, PolyPlus Transfection SA) in a
final volume of 100ul. These treatments were repeated every five days for 4 cycles (days 15,
20, 25, 30). In addition, in vivo dilution xenotransplantation assays were performed in NOD/
SCID/IL2Rγ-/- mice. Mice were evaluated on a weekly basis for tumor formation. All mice
were maintained in accordance with Dana-Farber Cancer Institute Animal Care and Use
Committee procedures and guidelines.
Purification of CD44high/CD24low and CD44low/CD24high Cells From Patients with TNBC
Five human invasive triple negative ductal carcinoma tissues (stage III) were used in our
experiments15. Immunomagnetic purification of CD44high/CD24low and CD44low/CD24high
cells was performed according to Shipitsin et al27. Briefly, the breast tissues were minced
into small pieces (1mm) using a sterile razor blade. The tissues were digested with 2mg/ml
collagenase I (C0130, Sigma) and 2mg/ml hyalurinidase (H3506, Sigma) in 37°C for 3h.
Cells were filtered, washed with PBS and followed by Percoll gradient centrifugation. The
first purification step was to remove the immune cells by immunomagnetic purification
using an equal mix of CD45 (leukocytes), CD15 (granulocytes), CD14 (monocytes) and
CD19 (B cells) Dynabeads (Invitrogen). The second purification step was to isolate
fibroblasts from the cell population by using CD10 beads for magnetic purification. The
third step was to isolate the endothelial cells by using an “endothelial cocktail” of beads
(CD31 BD Pharmingen cat no. 555444, CD146 P1H12 MCAM BD Pharmingen cat no.
550314, CD105 Abcam cat no. Ab2529, Cadherin 5 Immunotech cat no. 1597, and CD34
BD Pharmingen cat no. 555820). In the final step the CD44high cells were purified from the
remaining cell population using CD44 beads. These cells were sorted for CD44high/CD24low
cells, CD24high cells were also purified using CD24 beads. These cells were sorted for
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tCD44low/CD24high cells. These cell populations were sorted again with CD44 antibody
(FITC-conjugated) (555478, BD Biosciences) and CD24 antibody (PE-conjugated) (555428,
BD Biosciences) in order to increase their purity (>99.2% in all cases).
Gene Expression Microarray Analysis
MDA-MB-231 cells infected with control shRNA or XBP1 shRNA lentiviruses grown in
glucose free medium were treated in 0.1% O2 in a hypoxia chamber for 24h. Total RNA was
extracted by using RNeasy mini kit with on column DNase digestion (QIAGEN). Biotin
labeled cRNA was prepared from 1 μg of total RNA, fragmented, and hybridized to
Affymetrix human U133 plus 2.0 expression array. All Gene expression microarray data
were normalized and summarized using RMA. The differentially expressed genes were
identified using Limma (q ≤10%).
Motif Analysis
Flanking sequences around the summits (±300 bp ) of the top 1,000 XBP1 binding sites
were extracted and the repetitive regions in these flanking sequences were masked. The
consensus sequence motifs were derived using Seqpos.
XBP1 Signature Generation
The XBP1 signature was generated by integrative analysis of of ChIP-seq and differential
expression data using the method as previously described28. Briefly, we first calculated the
regulatory potential for a given gene, Sg, as the sum of the nearby binding sites weighted by
the distance from each site to the TSS of the gene:  , where k is the
number of binding sites within 100 kb of gene g and Δi is the distance between site i and the
TSS of gene g normalized to 100 kb (e.g., 0.5 for a 50 kb distance). We then applied the
Breitling's rank product method to combine regulatory potentials with differential expression
t-values to rank all genes based on the probability that they were XBP1 targets. Only genes
with at least one binding site within 100 kb from its TSS and a differential expression t-
value above the 75th percentile were considered. The FDR of XBP1 target prediction was
estimated by permutation. At a FDR cutoff of 20% and differential expression fold-change
cutoff of 1.5, we obtained 96 up-regulated genes (HUGO gene symbol) as direct targets of
XBP1.
Survival Analysis
We performed survival analysis using an aggregated compendium of gene expression
profiles of 383 TNBC samples from 21 breast cancer datasets21. Of the 96 XBP1 signature
genes, 70 genes had corresponding probes in this dataset. To avoid potential confounding
factors such as heterogeneity among the samples, we randomly split all 383 TNBC samples
into two datasets with similar size (193 and 190 cases) and evaluated the correlation of the
XBP1 gene signature with relapse free survival using these two datasets respectively. We
separated patients into two subgroups: one with higher and the other with lower expression
of the XBP1 signature. The subgroup classification was performed as described
previously29. Patients were considered to have a higher XBP1 signature if they had average
expression values of all the genes in the XBP1 signature above the 58th percentile29.
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tKaplan-Meier survival analysis was performed and log-rank test was used to assess the
statistical significance of survival difference between these 2 groups. We also performed
multivariate Cox regression analysis to evaluate the significance of the association between
XBP1 signature and relapse-free survival in the presence of other clinical variables
including tumor stage, tumor grade and the treatment with chemotherapy. A similar analysis
was performed for the HIF pathway signature (VEGFA, PDK1, DDIT4, SLC2A1, KDM3A,
NDRG1, PFKFB3, PIK3CA, RORB, CREBBP, PIK3CB, HK2 and EGLN1). Similar to the
analysis for TNBC, the survival analysis was performed for ER+ breast cancer using gene
expression profiles and clinical annotations of 209 ER+ breast cancer patients30.
Virus Production and Infection
The Phoenix packaging cell line was used for the generation of ecotropic retroviruses and
the 293T packaging cell line was used for lentiviral amplification. In brief, viruses were
collected 48 and 72 hr after transfection, filtered, and used for infecting cells in the presence
of 8 μg/ml polybrene prior to drug selection with puromycin (2 μg/ml). shRNA constructs
were generated by The Broad Institute. Targeting of GFP mRNA with shRNA served as a
control. Optimal targeting sequences identified for human XBP1 were 5′-
GACCCAGTCATGTTCTTCAAA-3′, and 5′- GAACAGCAAGTGGTAGATTTA-3′,
respectively. Knockdown efficiency was assessed by real-time PCR for XBP1.
Luciferase Assay
For Fig. 3f, MDA-MB-231 cells were co-transfected with 3×HRE luciferase (3×HRE-Luc)
plasmid and XBP1s overexpression construct or control vector by using Lipofectamine 2000
(Invitrogen). A Renilla luciferase plasmid (pRL-CMV from Promega) was co-transfected as
an internal control. Cells were harvested 36 hr after transfection, and the luciferase activities
of the cell lysates were measured by using the Dual-luciferase Reporter Assay System
(Promega). For Fig. 3e, MDA-MB-231 cells were co-transfected with 3×HRE-Luc and two
inducible XBP1 shRNA construct (in pLKO-Tet-On vector) or control shRNA construct by
using Lipofectamine 2000 (Invitrogen). Cells were treated with doxycycline for 48h and
hypoxia for 24h before the luciferase activities of the cell lysates were measured.
Statistical analysis
The significance of differences between treatment groups was measured with a Student's t-
test. P values of less than 0.05 were considered statistically significant.
Coimmunoprecipitation
Transfected cells were lysed in cell lysis buffer (50 mM Tris HCl, pH 8.0, 150 mM NaCl, 1
mM EDTA, 1% Nonidet P-40, and 10% glycerol with protease inhibitor cocktail) for 1 hour.
M2 beads (Sigma) were incubated with the whole cell extracts at 4°C for overnight. The
beads were washed with cell lysis buffer four times. Finally, the beads were boiled in 2x
sample buffer for 10 minutes. The eluents were analyzed by Western blot. Nuclear extracts
were used to perform the endogenous co-IP. Briefly, 5 mg of nuclear extracts were
incubated with 5 μg of anti-HIF1α antibody (Novus Biologicals, NB100-479) at 4°C for
overnight. The protein complexes were precipitated by addition of protein A agarose beads
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t(Roche) with incubation for 4 hr at 4°C. The beads were washed four times and boiled for 5
min in 2x sample buffer.
Real-time PCR analysis
1 μg of RNA sample was reverse-transcribed to form cDNA, which was subjected to SYBR
Green based real-time PCR analysis. Primers used for β-actin forward: 5’-
CCTGTACGCCAACACAGTGC-3’ and reverse 5’- ATACTCCTGCTT GCTGATCC-3’;
for VEGFA forward 5’- CACACAGGATGGCTTGAAGA -3’ and reverse 5’-
AGGGCAGAATCATCACGAAG-3’; for PDK1 forward 5’-
GGAGGTCTCAACACGAGGTC -3’ and reverse 5’- GTTCATGTCACGCTGGGTAA -3’;
for GLUT1 forward 5’- TGGACCCATGTCTGGTTGTA -3’ and reverse 5’-
ATGGAGCCCAGCAGCAA -3’; for JMJD1A forward 5’-
TCAGGTGACTTTCGTTCAGC-3’ and reverse 5’- CACCGACGTTACCAAGAAGG-3’;
for DDIT4 forward 5’- CATCAGGTTGGCACACAAGT-3’ and reverse 5’-
CCTGGAGAGCTCGGACTG-3’; for MCT4 forward 5’-TACATGTAGACGTGGGTCGC
– 3’ and reverse 5’ CTGCAGTTCGAGGTGCTCAT – 3’; for XBP1 splicing forward 5’-
CCTGGTTGCTGAAGAGGAGG-3’ and reverse 5’-CCATGGGGAGATGTTCTGGAG
-3’; for XBP1 total forward 5’-AGGAGTTAAGACAGCGCTTGGGGATGGAT-3’ and
reverse 5’-CTGAATCTGAAGAGTCAATACCGCCAGAAT-3’;
ChIP-re-ChIP
XBP1 antibody was cross-linked to protein G-Sepharose beads using dimethylpimelimidate
to prevent the leaching of antibody during sodium dodecyl sulfate (SDS) elution. The beads
were then incubated with chromatin extracts overnight. Subsequently, the beads were
washed and eluted with 1% SDS elution buffer at 37°C for 45 minutes. The eluate was
diluted to a final SDS concentration of 0.1% and incubated with fresh antibody-bound beads
for the second immunoprecipitation (IP). For the final round of IP, washed beads were
eluted with 1% SDS elution buffer at 68°C for 30 minutes. Eluate was decrosslinked in the
presence of pronase and heated at 68°C for 6 hours, and DNA was purified by phenol-
chloroform extraction.
Glutathione S-Transferase Pulldown Assay
Various deletion fragments of XBP1s were cloned into pET42b (Novagen). The plasmids
were transformed into BL21 Escherichia coli. The XBP1s proteins were expressed and
purified with glutathione (GSH)-Sepharose beads (GE healthcare). The purified proteins
were bound to GSH beads and incubated with HIF1α-overexpressed cell lysates for 2 hours
in 4°C. The beads were washed six times with cell lysis buffer. The eluents were analyzed
by Western blot.
DNA-binding assay
Nuclear protein (150 μg) was incubated for 1 h at 4 °C with a biotinylated probe containing
wild-type or mutated HIF1α binding site plus streptavidin-dynabeads (Invitrogen) in binding
buffer (100 mM NaCl, 10 mM Tris-HCl, pH 7.6, 0.1 mM EDTA, 1 mM dithiothreitol, 5%
glycerol, 1 mg/ml of BSA and 20 μg/ml of poly(dI:dC), plus protease inhibitors).
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immunoblot for XBP1s or HIF1α.
Transmission Electron Microscopy
Cells were washed with serum-free media then fixed with a modified Karmovsky's fix of
2.5% glutaraldehyde, 4% parafomaldehye and 0.02% picric acid in 0.1M sodium caocdylate
buffer at pH7.2. Following a secondary fixation in 1% osmium tetroxide, 1.5% potassium
ferricyanide, samples were dehydrated through a graded ethanol series, and embedded in
situ in an epon analog resin. En face ultrathin sections were cut on a Leica Ultractu S
Ultramicrotome (Leica). Sections were collected on copper grids and further contrasted with
lead citrate and viewed on a JEM 1400 electron microscope (JEOL, USA, Inc., Peabody,
MA) operated at 100 kV. Digital images were captured on a Veleta 2K x 2K CCD camera
(Olympus-SIS, Germany).
Caspase 3 ELISA Assay
Quantification of cleaved Caspase-3 activity was performed using the PathScan Cleaved
Caspase-3 (Asp175) sandwich ELISA kit (#7190, Cell Signaling) according to the
manufacturer's recommendations.
Immunohistochemical Staining
We fixed xenograft tumor tissues in 4% paraformaldehyde and performed
immunohistochemistry on 5-μm-thick paraffin sections after heat induced antigen retrieval.
The following primary antibodies were used: CD31 (1:50, Abcam, ab28364), Cleaved
Caspase 3 (1:200, Cell Signaling, #9664), CD44 (1:100, Novocastra), Ki67 (1:50, Dako,
Clone MIB-1), and Carbonic Anhydrase IX (1:40, Novus Biologicals). Subsequently, we
incubated the slides with biotinylated secondary antibody and ABC-HRP (both from Vector
Lab). EnVision+ system (Dako) was used to amplify Caspase 3 and Carbonic Anhydrase IX.
Mouse on Mouse ImmPRESS Polymer Kit (Vector Lab) was applied to increase CD44
signal to noise ratio. For all slides, final detectable signal was visualized by DAB as the
location of antigens. After counterstaining with hematoxylin, slides were mounted.
Immunoblot Analysis
Total cell extracts or nuclear extracts were separated by SDS-PAGE and transferred to
PVDF membranes. IRE1α phosphorylation was monitored by Phos-tag SDS-PAGE. PERK
phosphorylation was monitored by 5% SDS-PAGE. The following antibodies were used for
immunoblot analysis: anti-XBP1s (BioLegend, 619502); anti-PERK (Cell signaling, #5683);
anti-IRE1α (Cell Signaling, #3294); anti-ATF6 (Cosmo bio, BAM-73-500-EX); anti-ATF4
(Santa Cruz, sc-200); anti-Hsp90 (Santa Cruz, sc-7947), anti-TBP (Abcam, 51841); anti-
EIF2α (Santa Cruz, sc-11386); anti-phospho-EIF2α (Cell Signaling, #9721).
Chen et al. Page 11
Nature. Author manuscript; available in PMC 2014 October 03.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tExtended Data
Extended Data Figure 1. Effect of XBP1 silencing on TNBC cells and UPR
a, Activation of UPR in different breast cancer cells. Immunoblot of PERK phosphorylation,
IRE1α activation (phos-tag SDS-PAGE), and EIF2α phosphorylation in whole cell lysates,
and ATF6α processing (pATF6α) in nuclear extract of basal-like breast cancer cells (1:
HCC1937; 2: MDA-MB-231; 3: SUM159; 4: MDA-MB-157; 5: HCC70) and luminal breast
cancer cells (6: ZR-75-1; 7: T47D; 8: MCF7). TM: Positive control (whole cell lysates or
nuclear extracts from MDA-MB-231 cells treated with 5μg/ml tunicamycin for 6 hours).
HSP90 was used as loading control for whole cell lysates, TBP was used as loading control
for nuclear extract. b, Transmission electron microscopic analysis of ER in basal-like and
luminal breast cancer cell lines. Black arrows indicate the endoplasmic reticulum. All
images are at 30,000× magnification. Scale bar represents 1μM. c, Quantification of soft
agar colony formation and number of invasive cells in untreated and control shRNA or
XBP1 shRNA infected breast cancer cells. Experiments were performed in triplicate and
data are shown as mean ± SD. **p<0.01. d, Quantitative RT-PCR analysis of XBP1
expression in MDA-MB-231 cells infected with lentiviruses encoding doxycycline (DOX)
inducible shRNAs against XBP1 or scrambled LacZ control, in the presence or absence of
doxycycline for 48h. Data are presented relative to β-actin and shown as mean ± SD of
technical triplicates. e-f, Knockdown efficiency of total XBP1 (e) and XBP1s (f) in MDA-
MB-231 derived xenograft tumor (as in Fig.1d). Data are presented relative to β-actin. n=5.
g, Bioluminescent images of orthotopic tumors formed by luciferase expressing MDA-
MB-231 cells infected with different lentiviruses. A total of 1.5×106 cells were injected into
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tthe fourth mammary glands of nude mice. Bioluminescent images were obtained 1 week
later and serially after mice were begun on chow containing doxycycline (Dox) (day 10).
Pictures shown are the day 10 images (Before Dox) and day 45 images (After Dox). h,
Effect of XBP1 knockdown on ER stress marker BIP expression in MDA-MB-231 derived
xenograft tumors. Quantitative RT-PCR analysis of BIP expression in shCtrl or shXBP1
xenograft tumor. Data are presented relative to β-actin. n=5. i, Immunoblot of IRE1α
activation (phos-tag SDS-PAGE) and PERK phosphorylation in whole cell lysates; ATF6α
processing and ATF4 expression in nuclear extracts of two shCtrl or shXBP1 xenograft
tumors. HSP90 was used as loading control for whole cell lysates, TBP was used as loading
control for nuclear extract. j-k, Tumor growth of untreated or control shRNA, or XBP1
shRNA treated MDA-MB-436 (j) or HBL-100 cells (k) in nude mice. Data are shown as
mean ± SD of biological replicates (n=3). **p<0.01. Tx: Treatment with shRNA. l, Kaplan-
Meier tumor free survival curve of mice from Fig. 1f. m, Tumor growth (mean ± SEM) of
BCM-2147 tumors as in Fig. 1f (Scr siRNA: n=7; XBP1 siRNA: n=2).
Extended Data Figure 2. Effect of XBP1 on tumor relapse and CD44high/CD24low cells
a, Tumor growth of MDA-MB-231 cells untreated or treated with paclitaxel (20mg/kg), or
paclitaxel + control shRNA, or paclitaxel + XBP1 shRNA in nude mice. TX: treatment with
paclitaxel or paclitaxel+ shRNA. Data are shown as mean ± SD of biological replicates
(n=5). b, Number of mammospheres per 1,000 cells generated from day 20 xenograft tumors
under different treatments as indicated under normoxic or hypoxic condition (0.1% O2).
Data are shown as mean ± SD of biological replicates (n=3). * denotes significantly
different from paclitaxel+shCtrl control in each treatment, *p<0.05, **p<0.01. c, Effect of
XBP1 knockdown on cell death in hypoxic regions (assessed by CA9 and cleaved caspase3
staining) or accumulation of CD44high/CD24low cells (assessed by CD44 staining).
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tImmunohistochemical staining of CA9 and Cleaved Caspase 3 (consecutive sections)
showed that cell death was not induced in hypoxic region in XBP1 knockdown tumors.
Immunohistochemical staining of CD44 showed significant reduction of CD44 expression in
XBP1 knockdown tumors. All tumor sections are from MDA-MB-231 derived xenograft
with different treatment as indicated. d, Knockdown efficiency of XBP1 in MCF10A-ER-
Src cells. Data are shown as mean ± SD of technical triplicates. e, Left panel: Flow
cytometry analysis of CD44 and CD24 expression of TAM treated (36h) MCF10A ER-Src
cells infected with control shRNA or XBP1 shRNA encoding lentivirus. Right panel:
Percentage of CD44high/CD24low cells in TAM (4-OH-tamoxifen) treated MCF10A-ER-Src
cells infected with control shRNA or XBP1 shRNA encoding lentivirus. Experiments were
performed in triplicate and data are shown as mean ± SD. *p<0.05. f, Number of
mammospheres per 1,000 cells generated by TAM treated MCF10A ER-Src cells
uninfected, or infected with control shRNA or XBP1 shRNA encoding lentivirus.
Experiments were performed in triplicate and data are shown as mean ± SD. g, Cell viability
assay (Cell-titer Glo) on CD44high/CD24low or CD44low/CD24high cells isolated from TAM
treated MCF10A-ER-Src cells infected with control shRNA or XBP1 shRNA encoding
lentivirus (72h after infection). Data were normalized to the control (cell infected with
shCtrl). Experiments were performed in triplicate and data are shown as mean ± SD. h,
Cleaved caspase 3 ELISA assays on CD44high/CD24low or CD44low/CD24high cells isolated
from TAM treated MCF10A-ER-Src cells infected with control shRNA or XBP1 shRNA
encoding lentivirus (72h after infection). Experiments were performed in triplicate and data
are shown as mean ± SD.
Extended Data Figure 3. Effect of XBP1 on CD44high/CD24low cells
a, UPR markers are upregulated in CD44high/CD24low cells. Quantitative RT-PCR analysis
of UPR markers BIP, CHOP, ERDJ4, HERP and MBTPS1 in CD44low/CD24high cells and
CD44high/CD24low cells sorted from two TNBC patients. Data are shown as mean ± SD of
technical triplicates. *p<0.05, **p<0.01. b, XBP1s overespression in CD44low/CD24high
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tcells generates mammosphere-forming ability. Number of mammospheres per 1,000 cells
generated by sorted CD44low/CD24high cells transduced with empty vector or XBP1s
expressing retrovirus. Experiments were performed in triplicate and data are shown as mean
± SD. c, CD44low/CD24high cells overexpressing XBP1s are more resistant to
chemotherapy. MTT assay was performed to measure the dose-response curves of CD44low/
CD24high cells or CD44low/CD24high cells expressing XBP1s treated with doxorubicin.
Experiments were performed in triplicate and data are shown as mean ± SD. *p<0.05,
**p<0.01. d, 1000 or 100 CD44low/CD24high cells sorted from transformed MCF10A ER-
Src cells or CD44low/CD24high cells overexpressing XBP1s were injected into NOD/SCID/
IL2Rγ-/-mice and the incidence of tumors was monitored. e, 10 CD44low/CD24high cells
sorted from two human patients with TNBC or CD44low/CD24high cells overexpressing
XBP1s were injected into NOD/SCID/IL2Rγ-/-mice and the incidence of tumors was
monitored.
Extended Data Figure 4. HIF1α is a co-regulator of XBP1
a, Identification of XBP1 motif in MDA-MB-231 ChIP-seq dataset. Matrices predicted by
the de novo motif-discovery algorithm Seqpos. p<1.08×10-30. b, Induction of XBP1 splicing
by hypoxia. RT-PCR analysis of the ratio of XBP1s to total XBP1 in MDA-MB-231 cells
cultured under normoxic condition or hypoxic condition (0.1% O2) for 24h. Data are shown
as mean ± SD of technical triplicates. **p<0.01. c, Induction of XBP1 splicing by glucose
deprivation. RT-PCR analysis of the ratio of XBP1s to total XBP1 in MDA-MB-231 cells
cultured in normal medium or glucose free medium for 24h or 48h. Data are shown as mean
± SD of technical triplicates. *p<0.05. d, Induction of XBP1 splicing by oxidative stress.
RT-PCR analysis of the ratio of XBP1s to total XBP1 in MDA-MB-231 cells untreated or
treated with different dose of H2O2 for 1h, 4h or 24h. Data are shown as mean ± SD of
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ttechnical triplicates. e, Western blotting analysis of XBP1s expression in nuclear extract of
MDA-MB-231 cells cultured under normoxia or hypoxia (0.1% O2) and glucose free
condition for 16h. Lamin B was used as loading control. f, Venn diagram showing the
overlap between XBP1 targets in MDA-MB-231 breast cancer cells cultured under
normoxic condition (untreated) or hypoxia and glucose deprivation condition (treated). g,
Motif enrichment analysis in the XBP1 binding sites in untreated or stressed (0.1% O2 and
glucose deprivation: HG) MDA-MB-231, Hs578T or T47D cells. The 1kb region
surrounding the summit of the XBP1 peak is equally divided into 50 bins. The average
HIF1α motif occurrence over top 1000 XBP1 peaks in each bin is plotted. The
corresponding p-values of each condition are listed as follows: M231_UN: 7.78×10-20;
M231_HG: <1.08×10-30; Hs578T_HG: <1.08×10-30, T47D_HG: 6.14×10-6. h, FLAG-
tagged HIF1α and XBP1s were co-expressed in 293T cells, and the cells were treated in
0.1% O2 for 16h. Co-IP was performed with M2 anti-FLAG antibody. Western blot was
carried out with anti-XBP1s antibody, anti-FLAG antibody or anti-HIF1α antibody. Empty
vector was used as control. i, Nuclear extracts from Hs578T cells treated with Tunicamycin
(1μg/ml, 6h) in 0.1% O2 (16h) were subjected to co-IP with anti-HIF1α antibody or rabbit
IgG. Western blot was carried out with anti-XBP1s antibody or anti-HIF1α antibody. j, HA-
tagged HIF2α and XBP1s were co-expressed in 293T cells, and the cells were treated in
0.1% O2 for 16h. Co-IP was performed with anti-HA antibody. Western blot was carried out
with anti-XBP1s antibody or anti-HA antibody. Empty vector was used as control. k,
Localization of XBP1s and HIF1α in MDA-MB-231 cells. Western blotting analysis of
XBP1s and HIF1α expression in cytosolic extracts and nuclear extracts of MDA-MB-231
cells cultured under 0.1% O2 condition for 24h. HSP90 and TBP were used as control. l,
XBP1u is not expressed in MDA-MB-231 cells. Western blotting analysis of XBP1u in
MDA-MB-231 cells untreated or treated with 1μM or 10μM MG132 for 4h. HSP90 was
used as loading control. m, Schematic diagram of full-length and truncated forms of XBP1s
protein. n, A GST pull down assay was performed using GST-tagged XBP1s proteins and
293T cell lysates overexpressing HA-tagged HIF1α. Western blotting was performed with
an anti-HA antibody. Lower panel: Coomassie blue staining of GST-tagged different
truncated forms of XBP1s proteins.
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tExtended Data Figure 5. XBP1 and HIF1α co-occupy HIF1α targets
a, Track view of XBP1 ChIP-seq density profile (two biological replicates) on HIF1α target
genes. b, XBP1 and HIF1α co-bind to DDIT4, VEGFA, and PDK1 promoters under hypoxic
conditions. A ChIP assay was performed using anti-XBP1 or anti-HIF1α antibody to detect
enriched fragments. GST antibody was used as mock ChIP control. c, XBP1 and HIF1α co-
bind to JMJD1A and JMJD2C promoters under hypoxic conditions. Upper panel: Schematic
diagram of the primer locations across the JMJD2C or JMJD1A promoter. Grey boxes
indicate exon. A ChIP assay was performed using anti-XBP1 polyclonal antibody or anti-
HIF1α polyclonal antibody to detect enriched fragments. Fold enrichment is the relative
abundance of DNA fragments at the amplified region over a control amplified region. GST
antibody was used as mock ChIP control. d, XBP1s and HIF1α co-occupy JMJD1A, DDIT4,
NDRG1, PDK1 and VEGFA promoters. A ChIP-re-ChIP assay was performed using the
anti-XBP1s antibody first (X). The eluants were then subjected to a second ChIP assay using
an anti-HIF1α antibody (XH) or a control IgG antibody (XC). All ChIP Data (b-d) are
shown as mean ± SD of technical triplicates. Results show a representative of two
independent experiments. *p<0.05; **p<0.01. e, HIF1α, but not XBP1s, binds to a probe in
Twist promoter in 293T cells. DNA pull down assay was used to analyze the binding of
XBP1s or HIF1α on a probe in Twist promoter. The nuclear extracts of 293T cells
overexpressing XBP1s or Flag-HIF1α was incubated with the wild-type probe and
immunoblot analysis was performed with anti-XBP1s or anti-Flag antibody. f, XBP1s binds
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tto Twist promoter in MDA-MB-231 cells under 0.1% O2. The nuclear extract of MDA-
MB-231 cells cultured under 0.1% O2 for 24h was incubated with the wild-type or mutant
probe (HIF1α consensus sequence was mutated) and immunoblot analysis was performed
with anti-XBP1s or anti-HIF1α antibody. The lower panel shows the sequence of the probes
used. g, 3xHRE reporter was co-transfected with XBP1s expression plasmid or empty vector
into MDA-MB-231 cells and luciferase activity measured. Experiments were performed in
triplicate and data are shown as mean ± SD. **p<0.01. h, RT-PCR analysis of XBP1
expression as in (g). Data are shown as mean ± SD of technical triplicates.
Extended Data Figure 6. XBP1 regulates HIF1α targets
a, Plot from GSEA showing enrichment of the HIF1α mediated hypoxia response pathway
in XBP1-upregulated genes. b, Quantitative RT-PCR analysis of VEGFA, PDK1, GLUT1,
and DDIT4 expression after knockdown of XBP1 in MDA-MB-231 under both normoxic or
hypoxic conditions. c, Quantitative RT-PCR analysis of VEGFA, PDK1, GLUT1, MCT4,
JMJD1A and XBP1 expression after knockdown of XBP1 in Hs578T cells treated with 0.1%
O2 for 24h. Results are presented relative to β-actin expression. Experiments were
performed in triplicate and data are shown as mean ± SD. *p<0.05, **p<0.01. d, Plot from
GSEA showing no enrichment of the HIF1α mediated hypoxia response pathway in XBP1-
regulated genes in T47D cells (p=0.1684). e-k, Cooperative binding of XBP1 and HIF1α on
common targets. e, Immunoblotting analysis of control MDA-MB-231 cell lysates and
XBP1 knockdown lysates (treated with 0.1% O2 for 24h) were performed using anti-HIF1α
or anti-HSP90 antibody. f-g, Chromatin extracts from control MDA-MB-231 cells or XBP1
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tknockdown MDA-MB-231 cells (treated with 0.1% O2 for 24h) were subjected to ChIP
using anti-XBP1s antibody (f), or anti-RNA polymerase II antibody (g). The primers used to
detect ChIP-enriched DNA were the peak pair of primers in JMJD1A, DDIT4, NDRG1,
PDK1 and VEGFA promoters (Supplementary Table 3). Primers in the β-actin region were
used as control. h-i, Chromatin extracts from control MDA-MB-231 cells or HIF1α
knockdown MDA-MB-231 cells (treated with 0.1% O2 for 24h) were subjected to ChIP
using anti-HIF1α antibody (h), or anti-RNA polymerase II antibody (i). j-k, Chromatin
extracts from control MDA-MB-231 cells or XBP1 knockdown MDA-MB-231 cells (treated
with 1% O2 for 24h) were subjected to ChIP using anti-HIF1α antibody (j), and anti-XBP1s
antibody (k). All ChIP Data (f-k) are shown as mean ± SD of technical triplicates. Results
show a representative of two independent experiments. *p<0.05; **p<0.01. l, Quantitative
RT-PCR analysis of VEGFA, PDK1, GLUT1, and JMJD1A after knockdown of XBP1 in
MDA-MB-231 cells treated with 1% O2 for 24h. Results are presented relative to β-actin
expression. Data are shown as mean ± SD of technical triplicates. *p<0.05, **p<0.01.
Extended Data Figure 7. Overexpression of constitutively activated HIF1α rescues XBP1
knockdown phenotype
a, Immunoblotting analysis of cell lysates of MDA-MB-231 cells infected with retrovirus
encoding control vector or HA-HIF1α dPA was performed using anti-HA or anti-actin
antibody. b, XBP1 splicing is not affected by HIF1α or HIF2α activation. RT-PCR analysis
of the ratio of XBP1s to total XBP1 in MDA-MB-231 cells expressing control vector, HA-
HIF1α dPA or HA-HIF2α dPA. Expression of HA-HIF1α dPA is shown in (a) and
expression of HIF2α is shown in the right panel. c, XBP1 splicing is not affected by HIF1α
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tor HIF2α depletion. RT-PCR analysis of the ratio of XBP1s to total XBP1 in MDA-MB-231
cells infected with control, shHIF1α or shHIF2α lentivirus. Knockdown efficiency of
HIF1α or HIF2α is shown in the middle and right panels. d-e, Expression of constitutively
activated HIF1α doesn't affect XBP1 expression (d), but restores HIF1α targets expression
(e). RT-PCR analysis of XBP1 total (d), XBP1s (d) and VEGFA, PDK1, DDIT4 (e) in
control shRNA (shCtrl), XBP1 shRNA (shXBP1), or XBP1 shRNA plus constitutively
activated HIF1α (shXBP1+HIF1α dPA) infected MDA-MB-231 cells. Data (b-e) are shown
as mean ± SD of technical triplicates. *p<0.05, **p<0.01. f, Quantification of soft agar
colony formation in control shRNA (shCtrl), XBP1 shRNA (shXBP1), or XBP1 shRNA plus
constitutively activated HIF1α (shXBP1+HIF1α dPA) infected MDA-MB-231, MDA-
MB-468, or MDA-MB-157 cells. Experiments were performed in triplicate and data are
shown as mean ± SD. **p<0.01. g, Quantification of mammosphere formation in control
shRNA (shCtrl), XBP1 shRNA (shXBP1), or XBP1 shRNA plus constitutively activated
HIF1α (shXBP1+HIF1α dPA) infected MDA-MB-231 cells. Experiments were performed
in triplicate and data are shown as mean ± SD. **p<0.01. h, CD31 immunostaining of
tumors formed by MDA-MB-231 cells infected with control shRNA (shCtrl), XBP1 shRNA
(shXBP1) or XBP1 shRNA plus constitutively activated HIF1α (shXBP1+HIF1αdPA). i,
Silencing of HIF1α inhibits the XBP1s-sustained mammosphere forming ability.
Quantification of mammosphere formation in MCF10A cells expressing control vector,
XBP1s, XBP1s plus control shRNA or XBP1s plus HIF1α shRNA. Experiments were
performed in triplicate and data are shown as mean ± SD. **p<0.01.
Extended Data Figure 8. Schema depicting the interaction of XBP1 and HIF1α in TNBC
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tXBP1 and HIF1α cooperatively regulate HIF1α targets in TNBC. In the setting of a tumor
microenvironment, hypoxia further induces XBP1 activation, active XBP1s in turn interacts
with HIF1α to stimulate and augment the transactivation of HIF1 target genes that promote
cancer progression.
Extended Data Figure 9. Correlation of XBP1 with HIF1α in patients with TNBC
a-b, Expression of XBP1 signature is highly correlated with two public available hypoxia-
driven signatures in TNBC patients (a), but not in ER+ breast cancer patients (b). The
scatter-plot of XBP1 and two publicly available HIF1α signature (Left panel: HIF1α
pathway; Right panel: Hypoxia via HIF1α pathway) across different tumors were drawn for
TNBC (a) and ER+ breast cancer patients (b), respectively. The corresponding Pearson's
correlation coefficient (r) between XBP1 and HIF1α signature was shown. c-d, Kaplan-
Meier graphs demonstrating no significant association of the expression of the XBP1
signature (red line) (c) or HIF signature (d) with relapse free survival in estrogen receptor
positive breast cancer patients. The log-rank test P values are shown.
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tExtended Data Figure 10. Role of XBP1 in luminal breast cancer
a, XBP1 splicing is induced by hypoxia and glucose deprivation in luminal cancer cells. RT-
PCR of XBP1 splicing in T47D and SKBR3 cells under different treatments for 24h.
XBP1u: unspliced XBP1, XBP1s: spliced XBP1. Hypoxia: 0.1% O2. b. Left panel:
Quantification of soft agar colony formation in untreated and control shRNA or XBP1
shRNA infected breast cancer cells. Experiments were performed in triplicate and data are
shown as mean ± SD. **p<0.01. Right panel: effect of XBP1 depletion on soft agar colony
formation in luminal vs basal cell lines. Percentages of soft agar colonies formed from cells
infected with XBP1 shRNA lentivirus relative to the same cell line infected with shCtrl
lentivirus (set as 100%) are presented. 5 cell lines in each group (as in left panel) and data
are shown as mean ± SD. c, Tumor growth (mean ± SD) of ZR-75-1 cells treated with
control shRNA (n=4), paclitaxel (20mg/kg) + control shRNA (n=4), XBP1 shRNA (n=4) or
paclitaxel + XBP1 shRNA (n=3) in nude mice. TX: treatment with shRNA or paclitaxel+
shRNA. *denotes shXBP1 treated tumors significantly different from shCtrl treated tumors.
p<0.05. d, Number of mammospheres per 1,000 cells generated by control shRNA or XBP1
shRNA encoding lentivirus infected T47D or SKBR3 breast cancer cell lines cultured under
normoxia or hypoxia and glucose deprivation conditions (treated). Experiments were
performed in triplicate and data are shown as mean ± SD. e. Venn diagram showing the
overlap between XBP1 targets in MDA-MB-231, Hs578T cells and T47D cells cultured
under hypoxia and glucose deprivation conditions. f. XBP1s overexpression is not capable
of converting a luminal phenotype to basal phenotype. RT-PCR analysis of luminal markers
(CK8, CK18, CK19 and E-cadherin) and basal markers (CK5, CK14, p63, Fibronectin and
Vimentin) expression in luminal breast cancer cells (MCF7 or T47D) infected with
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tlentivirus encoding empty vector or XBP1s. Data are shown as mean ± SD of technical
triplicates.
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tFigure 1. XBP1 silencing blocks TNBC cell growth and invasiveness
a-b, RT-PCR analysis of XBP1 splicing in luminal and basal-like cell lines (a) or primary
tissues from 6 TNBC patients and 5 ER/PR+ patients (b). XBP1u: unspliced XBP1, XBP1s:
spliced XBP1. β-actin was used as loading control. c, Representative bioluminescent images
of orthotopic tumors formed by MDA-MB-231 cells as in (Extended Data 1d).
Bioluminescent images were obtained 5 days after transplantation and serially after mice
were begun on chow containing doxycycline (day 19) for 8 weeks. Pictures shown are the
day19 image (Before Dox) and day 64 image (After Dox). d, Quantification of imaging
studies as in (c). Data are shown as mean ± SD of biological replicates (n=8). *p<0.05,
**p<0.01. e. H&E, Ki67, cleaved Caspase 3 or CD31 immunostaining of tumors or lungs 8
weeks after mice were fed chow containing doxycycline. Black arrows indicate metastatic
nodules. f, Tumor incidence in mice transplanted with BCM-2147 tumor cells (10 weeks
post-transplantation). Statistical significance was determined by Barnard's test22, 23.
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tFigure 2. XBP1 is required for tumor relapse and CD44high/CD24lowcells
a, Tumor growth of MDA-MB-231 cells untreated or treated with doxorubicin (Dox), or
Dox + control shRNA, or Dox + XBP1 shRNA in athymic nude mice. Data are shown as
mean ± SD of biological replicates (n=5). TX: treatment. b, Number of mammospheres per
1,000 cells generated from day 20 xenograft tumors under different treatments as indicated.
Data are shown as mean ± SD of biological replicates (n=3). c, RT-PCR analysis of XBP1
splicing in TAM (tamoxifen) treated CD44low/CD24high and CD44high/CD24low cells. d,
The indicated number of TAM-treated MCF10A-ER-Src cells infected with control shRNA
or XBP1 shRNA were injected into NOD/SCID/IL2Rγ -/- mice and the tumor incidence
reported at 12 weeks post-transplantation. e, RT-PCR analysis of XBP1 splicing in
CD44low/CD24high and CD44high/CD24low cells purified from a TNBC patient. f, Number
of mammospheres per 1,000 cells generated from untreated and control shRNA or XBP1
shRNA encoding lentivirus infected primary tissue samples from five patients with TNBC.
Data are shown as mean ± SD of technical triplicates.
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tFigure 3. HIF1α is a co-regulator of XBP1
a, Motif enrichment analysis in the XBP1 binding sites in untreated or stressed (0.1% O2
and glucose deprivation: HG) MDA-MB-231 or Hs578T cells. The 1kb region surrounding
the summit of the XBP1 peak is equally divided into 50 bins. The average HIF1α motif
occurrence over top 1000 XBP1 peaks in each bin is plotted. The corresponding p-values of
each condition: M231_UN: 7.78×10-20; M231_HG: <1.08×10-30; Hs578T_HG:
<1.08×10-30. b, Nuclear extracts from MDA-MB-231 cells (treated with 0.1% O2 for 10h
first and then with 1μg/ml tunicamycin for another 6 hours in 0.1% O2) were subjected to
co-IP with anti-HIF1α antibody or rabbit IgG. c, Schematic of the luciferase reporter
constructs. 3xHRE reporter was co-transfected with doxycycline (DOX) inducible
constructs encoding control or two XBP1 shRNAs into MDA-MB-231 cells. Cells were
treated in 0.1% O2 for 24h and luciferase activity assayed. Experiments were performed in
triplicate and data are shown as mean ± SD. d, Gene expression microarray heatmap
showing that genes involved in the HIF1α mediated hypoxia response were differentially
expressed after XBP1 knockdown. e, RT-PCR analysis of HIF1α target genes expression
after knockdown of XBP1 in MDA-MB-231 derived xenograft tumors in NOD/SCID/
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tIL2γ-/- mice. Results are presented relative to β-actin expression. n=5. f, Plot showing the
genome-wide association between the strength of XBP1 binding and the occurrence of the
HIF1α motif. The signal of XBP1 ChIP-seq peaks is shown as a heatmap using red (the
strongest signal) and white (the weakest signal) color scheme. Each row shows ±300 bp
centered on the XBP1 ChIP-seq peak summits. Rows are ranked by XBP1 occupancy. The
horizontal blue lines denote the presence of the HIF1α motif. g-h, Chromatin extracts from
control, XBP1 knockdown (g) or HIF1α knockdown (h) MDA-MB-231 cells (treated with
0.1% O2 for 24h) were subjected to ChIP using anti-HIF1α (g) or anti-XBP1 antibodies (h).
Data are shown as mean ± SD of technical triplicates. Results show a representative of two
independent experiments. i. Growth curve of tumors formed by MDA-MB-231 cells infected
with inducible control shRNA (shCtrl), XBP1 shRNA (shXBP1) or XBP1 shRNA plus
constitutively activated HIF1α (shXBP1+HIF1α dPA). Mice were fed with doxycycline
chow from day 7. Data are shown as mean ± SD of biological replicates (n=5). *p<0.05,
**p<0.01.
Chen et al. Page 28
Nature. Author manuscript; available in PMC 2014 October 03.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 4. XBP1 genetic signature is associated with human TNBC prognosis
a, Heatmap showing the expression profile of genes bound by XBP1 and differentially
expressed after XBP1 knockdown. b,c, Kaplan-Meier graphs demonstrating a significant
association between elevated expression of the XBP1 signature (red line) and shorter relapse
free survival in two cohorts of patients with TNBC (b, and c). d, Kaplan-Meier graphs
showing significant association of elevated HIF1α gene signature expression (red line) with
shorter relapse free survival in a cohort of 383 TNBC patients. The log-rank test P values are
shown.
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